Received Feb 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 4 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 5 | — | — |
The caller reported the patient is asymptomatic/No additional AE reported.; A nurse reported a 43-year-old patient received 3 doses of GARDASIL9 in 2021 and the inadvertently received 2 additional doses in 2025. Exact dates of administration are unknown.; A nurse reported a 43-year-old patient received 3 doses of GARDASIL9 in 2021 and the inadvertently received 2 additional doses in 2025. Exact dates of administration are unknown.; This spontaneous report was received from a Nurse and refers to a(n) 43-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown exact date in 2021, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (formulation, lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. On an unknown exact date in 2021, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (formulation, lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. On an unknown exact date in 2021, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (formulation, lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. On an unknown exact date in 2025, the patient inadvertently received the fourth dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (formulation, lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis (extra dose administered). On an unknown exact date in 2025, the patient inadvertently received the fifth dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (formulation, lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis (extra dose administered). Exact dates of administration are unknown. The caller reported the patient was asymptomatic. No additional adverse event reported (no adverse event).